Education
About Us
Working with TipRanks
Follow Us
Palvella Therapeutics (PVLA)
NASDAQ:PVLA
PVLA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.20 - $29.27
Previous CloseN/A
Volume11.83K
Average Volume (3M)73.58K
Market Cap
$314.08M
Enterprise Value-$954.53K
Total Cash (Recent Filing)$74.87M
Total Debt (Recent Filing)$16.36M
Price to Earnings (P/E)―
Beta-0.16
Next Earnings
Mar 31, 2025EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.61
Shares Outstanding11,018,747
10 Day Avg. Volume111,055
30 Day Avg. Volume73,576
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)42.95
Price to Cash Flow (P/CF)63.60
P/FCF Ratio63.60
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.02
Enterprise Value/Ebitda0.13
Forecast
1Y Price Target
$49.25Price Target Upside82.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase 3 SELVA trial design reflects regulatory flexibility for ultra-rare conditions with no FDA-approved therapies, supported by Breakthrough Therapy, Fast Track, and Orphan Drug designations.
Market PotentialThe commercial opportunity for QTORIN in microcystic lymphatic malformations is compelling, with an estimated 20,000–30,000 addressable U.S. patients and no current standard-of-care.
Therapeutic DevelopmentPalvella Therapeutics is developing therapies for rare genetic skin diseases with significant unmet needs, which highlights a strong market potential.
Bears Say
Financial PerformancePVLA reported a FY24 net loss of approximately $17.4M and LPS of $7.83.
Financial SustainabilityManagement estimates current cash should provide runway into 2H27, covering various trials and submissions, indicating limited financial flexibility.
Regulatory ChallengesThe SELVA readout stands as a high-impact catalyst for Palvella, with the potential to de-risk QTORIN’s regulatory path and establish a new foothold in orphan dermatology, yet regulatory success remains uncertain.
---
Options Prices
Currently, No data available
---
Ownership Overview
3.52% Insiders
0.16% Mutual Funds
29.15% Other Institutional Investors
67.05% Public Companies and
Individual Investors
PVLA FAQ
What was Palvella Therapeutics’s price range in the past 12 months?
Palvella Therapeutics lowest stock price was $6.20 and its highest was $29.27 in the past 12 months.
What is Palvella Therapeutics’s market cap?
Palvella Therapeutics’s market cap is $314.08M.
When is Palvella Therapeutics’s upcoming earnings report date?
Palvella Therapeutics’s upcoming earnings report date is Mar 31, 2025 which is 3 days ago.
How were Palvella Therapeutics’s earnings last quarter?
Palvella Therapeutics released its earnings results on May 08, 2024. The company reported -$3.954 earnings per share for the quarter, missing the consensus estimate of N/A by -$3.954.
Is Palvella Therapeutics overvalued?
According to Wall Street analysts Palvella Therapeutics’s price is currently Undervalued.
Does Palvella Therapeutics pay dividends?
Palvella Therapeutics does not currently pay dividends.
What is Palvella Therapeutics’s EPS estimate?
Palvella Therapeutics’s EPS estimate is -0.64.
How many shares outstanding does Palvella Therapeutics have?
Palvella Therapeutics has 11,018,747 shares outstanding.
What happened to Palvella Therapeutics’s price movement after its last earnings report?
Palvella Therapeutics reported an EPS of -$3.954 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.391%.
Which hedge fund is a major shareholder of Palvella Therapeutics?
Currently, no hedge funds are holding shares in PVLA
---
Palvella Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.25 (82.61% Upside)
$49.25 (82.61% Upside)
Hedge Fund Trend
Decreased
By 12.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $51.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 38.4%
Last 30 Days ▲ 38.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.68%
12-Months-Change
Fundamentals
Return on Equity
-68.21%
Trailing 12-Months
Asset Growth
-65.44%
Trailing 12-Months
Company Description
Palvella Therapeutics
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
---
PVLA Stock 12 Month Forecast
Average Price Target
$49.25
▲(82.61% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Regeneron
―
Vertex Pharmaceuticals
―
SAGE Therapeutics
―
Best Analysts Covering PVLA
1 Year
1 Year Success Rate
3/4 ratings generated profit
1 Year Average Return
+61.25%
reiterated a buy rating 2 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +61.25% per trade.
---